Biosimilar Approval Is New Focus In Senate Critique Of FDA Guidance Policy
This article was originally published in The Pink Sheet Daily
Executive Summary
Commissioner Hamburg describes a Catch-22, warning that pressure to finalize guidances faster without more resources could result in fewer discretionary guidances, disappointing stakeholders.